← Leaderboards
Flora Luo
Harvard Medical School
$75,605
Attributed
$75,605
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $35.2K · FY2015–17$50K$37.5K$25K$12.5K$0
'15
'16
'17
Funding mix
By agency
NIH$75,605 · 1
By mechanism
F31$75,605 · 1
Top collaborators
No co-investigators on record.
Most similar at Harvard Medical School
Same institution · by research overlap
- Marc W Kirschner$55,400,682
- Elizabeth A White$5,103,815
- Jeremy Purvis$5,214,387
- Constance L Cepko$19,977,994
- Leon Peshkin$6,585,278
Others in their field
Top investigators on “Estrogens”
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$57,671,528
- Howard N Hodis · University Of Southern California$41,407,306
- Bert W O'Malley · Baylor College Of Medicine$33,037,840
- Susan E. Hankinson · University Of Massachusetts Amherst$30,484,553
- David Heimbrook · Leidos Biomedical Research, Inc.$29,568,910
- Norman Wolmark · Nsabp Foundation, Inc.$27,523,275
Research focus
EstrogensExhibitsEstrogen ReceptorsEstrogen Receptor PositiveCandidate Disease GeneCdc GenesBreast Cancer CellEsr1 GeneCell Cycle InhibitionCancer PatientCellsCessation Of LifeClinical PredictorsCombined Modality TherapyCdk4 GeneCancer EtiologyCell CycleEffective TherapyDeprivationDna BiosynthesisDrug EfficacyCell Cycle ProgressionE2f Transcription FactorsGenes
Grant awards (3)
Dissecting response and resistance to CDK4/6 inhibition in ER+ breast cancer$9,400
F31 · FY2017 · CA · contact PI
Dissecting response and resistance to CDK4/6 inhibition in ER+ breast cancer$30,980
F31 · FY2016 · CA · contact PI
Dissecting response and resistance to CDK4/6 inhibition in ER+ breast cancer$35,225
F31 · FY2015 · CA · contact PI